Base to Base biotech podcast 4: A new class of therapeutics, and biotech hiring in 2025

This week on the podcast, we have conversations about hiring in the lifesciences industry in 2025, and about a potential new class of synthetic therapeutics.Interview times: 02:49 ThirdLaw Molecular 21:14 Occam GlobalThirdLaw MolecularThirdLaw Molecular is a biotech company that has pioneered the discovery and development of Spiroligomer molecules – a groundbreaking new platform for targeted drug discovery.The company is designing and synthesizing libraries of billions of Spiroligomer-based molecules and is entering into research collaborations with pharmaceutical organizations to identify and optimize highly targeted drug-development candidates.ThirdLaw Molecular was founded in 2020 by our guest on the podcast, Christian Schafmeister, professor of Chemistry at Temple University, to advance his research into synthetic alternatives to proteins, with the mission of creating a revolutionary category of molecules that transform how diseases are diagnosed and treated – more safely and effectively.Occam GlobalBill Holodnak, founder and CEO of Occam Global, is our guest this week and talks about funding, what's driving biotech hiring in 2025, the hottest startup areas, hiring of chief business officers, what to look for in a CEO, and much more.Occam Global provides global executive recruiting, board recruiting, and leadership advisory services. With associates in New York, San Francisco, London, and Los Angeles, Occam serves clients in Europe the US, and Asia.To get in touch with guest suggestions, please email [email protected]

There are no comments yet.

Please log in to write the first comment.